作者
Bernhard Scheiner, Martha M Kirstein, Florian Hucke, Fabian Finkelmeier, Kornelius Schulze, Johann von Felden, Sandra Koch, Philipp Schwabl, Jan B Hinrichs, Fredrik Waneck, Oliver Waidmann, Thomas Reiberger, Christian Müller, Wolfgang Sieghart, Michael Trauner, Arndt Weinmann, Henning Wege, Jörg Trojan, Markus Peck‐Radosavljevic, Arndt Vogel, Matthias Pinter
发表日期
2019/5
期刊
Alimentary pharmacology & therapeutics
卷号
49
期号
10
页码范围
1323-1333
简介
Background
Programmed cell death protein‐1‐targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma.
Aim
To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real‐world cohort of patients with advanced hepatocellular carcinoma.
Methods
Sixty‐five patients treated with nivolumab (n = 34) or pembrolizumab (n = 31) between July 10, 2015 and December 31, 2018 (data cut‐off) across six centres in Austria and Germany were retrospectively analysed.
Results
Child‐Pugh class A/B/C was 32 (49%)/28 (43%)/5 (8%). Immunotherapy was used as systemic first‐/second‐/third‐/fourth‐line treatment in 9 (14%)/27 (42%)/26 (40%)/3 (5%) patients. Fifty‐four patients had at least one follow‐up imaging and were, therefore, available for radiological response assessment. The overall response and disease control rates were 12 …
学术搜索中的文章
B Scheiner, MM Kirstein, F Hucke, F Finkelmeier… - Alimentary pharmacology & therapeutics, 2019